Published • loading... • Updated
Study: Cancer Jab Eliminates Tumors in Patients
Researchers said the injection erased tumours in 15 patients and helped 42% of trial participants, offering a new option after chemotherapy and immunotherapy failed.
- On Sunday, researchers will present results at the American Society of Clinical Oncology meeting in Chicago showing amivantamab shrank or eradicated head and neck tumours in 43 of 102 patients, including 15 complete responses.
- This triple-action jab blocks EGFR and MET pathways while activating the immune system, targeting HPV-negative head and neck cancers that typically resist standard chemotherapy and immunotherapy.
- Carl Walsh joined the OrigAMI-4 trial at the Royal Marsden in July 2025, reporting his diet and speech returned to normal; most patients experienced mild side-effects, with fewer than one in 10 stopping treatment.
- Describing the responses as 'unprecedented,' Kevin Harrington, professor in biological cancer therapies at the Institute of Cancer Research, noted this represents a significant step forward for thousands of patients annually.
- Johnson is evaluating amivantamab in about 60 clinical trials across multiple cancer types, with similar results reported in lung cancer, signaling potential to extend beyond current head and neck applications.
Insights by Ground AI
43 Articles
43 Articles
Sensational Breakthrough: a New Injection Completely Eliminated Tumors in 15 Terminally Ill Patients
Amivantamab is unique in that it targets cancer cells through multiple mechanisms at once. The drug blocks a protein called EGFR, which helps tumors grow, inhibits the MET signaling pathway, which tumors often use to evade treatments, and also activates the immune system to fight cancer cells.
·Budapest, Hungary
Read Full Article
Doctors praised the "unprecedented" results of a clinical trial in 11 countries demonstrating that a triple injection against cancer can eradicate whole tumours in patients.
·Portugal
Read Full Article
Coverage Details
Total News Sources43
Leaning Left7Leaning Right10Center7Last UpdatedBias Distribution42% Right
Bias Distribution
- 42% of the sources lean Right
42% Right
L 29%
C 29%
R 42%
Factuality
To view factuality data please Upgrade to Premium
